Role of circulating endothelial cells in assessing the severity of systemic sclerosis and predicting its clinical worsening.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 01 2021
29 01 2021
Historique:
received:
29
01
2020
accepted:
09
12
2020
entrez:
30
1
2021
pubmed:
31
1
2021
medline:
16
11
2021
Statut:
epublish
Résumé
Endothelial damage and fibro-proliferative vasculopathy of small vessels are pathological hallmarks of systemic sclerosis (SSc). The consequence is the detachment of resident elements that become circulating endothelial cells (CECs). The aim of our study was to evaluate the potential of CECs as biomarker in SSc. We enrolled 50 patients with limited cutaneous (lcSSc) and diffuse cutaneous (dcSSc) subset of SSc, who underwent clinical evaluation to establish the organ involvement. CECs were measured by flow-cytometry utilizing a polychromatic panel. An evident difference was observed in CEC counts comparing controls to SSc patients (median 10.5 vs. 152 cells/ml, p < 0.0001) and for the first time, between the two subsets of disease (median lcSSc 132 vs. dcSSc 716 CEC/ml, p < 0.0001). A significant correlation was established between CECs and some SSc clinical parameters, such as digital ulcers, skin and pulmonary involvement, presence of Scl-70 antibodies, nailfold videocapillaroscopy patterns and EUSTAR activity index. After 12 months, CECs correlated with clinical worsening of patients, showing that a number higher than 414 CEC/ml is a strong negative prognostic factor (RR 5.70). Our results indicate that CECs are a direct indicator of systemic vascular damage. Therefore, they can be used as a reliable marker of disease severity.
Identifiants
pubmed: 33514797
doi: 10.1038/s41598-020-80604-7
pii: 10.1038/s41598-020-80604-7
pmc: PMC7846576
doi:
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2681Références
Ann Rheum Dis. 2017 Jan;76(1):270-276
pubmed: 27621285
Arthritis Rheum. 2004 Apr;50(4):1296-304
pubmed: 15077314
J Dermatol. 2016 Jan;43(1):29-38
pubmed: 26782004
Arterioscler Thromb Vasc Biol. 2012 Apr;32(4):1045-53
pubmed: 22282356
Autoimmun Rev. 2013 Jan;12(3):340-54
pubmed: 22743034
Blood. 2005 Jan 15;105(2):526-32
pubmed: 15374879
Autoimmun Rev. 2017 Aug;16(8):774-786
pubmed: 28572048
Arthritis Rheum. 2009 Aug;60(8):2490-8
pubmed: 19644851
Thromb Haemost. 2005 Feb;93(2):228-35
pubmed: 15711737
BMC Musculoskelet Disord. 2016 Aug 15;17(1):342
pubmed: 27526772
Blood. 2001 Jun 1;97(11):3658-61
pubmed: 11369666
Cytometry B Clin Cytom. 2005 Mar;64(1):1-8
pubmed: 15668988
Nephrol Dial Transplant. 2009 May;24(5):1495-9
pubmed: 19039027
Arthritis Res Ther. 2013 Apr 19;15(2):R55
pubmed: 23601622
J Rheumatol. 2000 Jan;27(1):155-60
pubmed: 10648032
Blood. 1999 May 1;93(9):2951-8
pubmed: 10216090
Arthritis Res Ther. 2003;5(2):80-93
pubmed: 12718748
Lancet. 2017 Oct 7;390(10103):1685-1699
pubmed: 28413064
Cytometry A. 2016 Mar;89(3):259-70
pubmed: 26305912
Semin Nucl Med. 1995 Oct;25(4):306-17
pubmed: 8545635
Thromb Haemost. 2006 Jul;96(1):45-52
pubmed: 16807650
Rheumatology (Oxford). 2001 Oct;40(10):1135-40
pubmed: 11600743
Front Immunol. 2015 Jun 08;6:272
pubmed: 26106387
Clin Exp Rheumatol. 2001 Sep-Oct;19(5):503-8
pubmed: 11579708
Ann Rheum Dis. 2007 Jun;66(6):754-63
pubmed: 17234652
J Thromb Haemost. 2012 May;10(5):931-9
pubmed: 22385979
Autoimmun Rev. 2011 Aug;10(10):641-6
pubmed: 21549220
Ann Rheum Dis. 2017 Aug;76(8):1327-1339
pubmed: 27941129
Autoimmun Rev. 2016 May;15(5):417-26
pubmed: 26802722
Sci Rep. 2018 Apr 11;8(1):5823
pubmed: 29643468
Autoimmun Rev. 2016 Nov;15(11):1094-1108
pubmed: 27497912
Clin Cancer Res. 2009 Jan 1;15(1):267-73
pubmed: 19118054
Rheumatology (Oxford). 2004 Apr;43(4):461-6
pubmed: 15024134
Ann Rheum Dis. 2013 Nov;72(11):1747-55
pubmed: 24092682
J Cell Mol Med. 2010 Jun;14(6A):1241-54
pubmed: 20132409